| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Brd4; CAP; HUNK1; MCAP; Bromodomain containing 4; chromosome associated protein; ;BRD4 |
| WB Predicted band size | 152 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human BRD4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于Brd4抗体的参考文献及其摘要概览：
---
1. **文献名称**：*Selective inhibition of tumor oncogenes by disruption of super-enhancers*
**作者**：Lovén, J. et al.
**摘要**：该研究利用Brd4抗体进行ChIP-seq分析，发现肿瘤细胞中致癌基因的超级增强子依赖Brd4的调控，破坏其结构可选择性抑制癌基因表达，为靶向治疗提供依据。
---
2. **文献名称**：*Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression*
**作者**：Dey, A. et al.
**摘要**：通过Brd4抗体的免疫共沉淀实验，揭示Brd4在细胞周期中招募P-TEFb复合体至染色体，调控G1期基因转录，影响细胞周期进程的分子机制。
---
3. **文献名称**：*Targeting MYC dependence through BET bromodomain inhibition*
**作者**：Delmore, J.E. et al.
**摘要**：研究采用Brd4抗体验证BET抑制剂JQ1的作用，证明抑制Brd4可阻断MYC驱动的肿瘤生长，为血液系统恶性肿瘤提供了新的治疗策略。
---
这些文献均通过Brd4抗体在机制探索或药物开发中发挥关键作用，涵盖癌症生物学和表观遗传调控领域。如需具体实验细节或更多文献，可进一步补充关键词或研究方向。
Brd4 (bromodomain-containing protein 4) is a member of the BET (bromodomain and extraterminal) protein family, which plays a critical role in regulating gene expression by interacting with acetylated histones and transcription-related complexes. It functions as an epigenetic reader, binding to acetylated lysine residues on chromatin to recruit mediators like P-TEFb (positive transcription elongation factor b), thereby facilitating transcriptional elongation of target genes. Brd4 is involved in diverse cellular processes, including cell cycle progression, DNA damage response, and inflammatory signaling. Its dysregulation has been linked to cancers, viral infections, and inflammatory diseases, making it a key therapeutic target.
Brd4 antibodies are essential tools for studying its biological functions and mechanisms. They are widely used in techniques such as chromatin immunoprecipitation (ChIP-seq), immunofluorescence, and Western blotting to detect Brd4’s expression, localization, and interactions with chromatin or other proteins. These antibodies also support research into BET inhibitors (e.g., JQ1. I-BET), which block Brd4’s bromodomains to suppress oncogene transcription. Validation of Brd4 antibodies is critical, as off-target binding to other BET family members (Brd2. Brd3. BrdT) can confound results. High-quality antibodies enable precise exploration of Brd4’s roles in disease pathways and drug development.
×
